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Abstract
Background: Systems approaches to studying drug-side-effect (drug-SE) associations are emerging as an active
research area for both drug target discovery and drug repositioning. However, a comprehensive drug-SE
association knowledge base does not exist. In this study, we present a novel knowledge-driven (KD) approach to
effectively extract a large number of drug-SE pairs from published biomedical literature.
Data and methods: For the text corpus, we used 21,354,075 MEDLINE records (119,085,682 sentences). First, we
used known drug-SE associations derived from FDA drug labels as prior knowledge to automatically find SE-related
sentences and abstracts. We then extracted a total of 49,575 drug-SE pairs from MEDLINE sentences and 180,454
pairs from abstracts.
Results: On average, the KD approach has achieved a precision of 0.335, a recall of 0.509, and an F1 of 0.392,
which is significantly better than a SVM-based machine learning approach (precision: 0.135, recall: 0.900, F1: 0.233)
with a 73.0% increase in F1 score. Through integrative analysis, we demonstrate that the higher-level phenotypic
drug-SE relationships reflects lower-level genetic, genomic, and chemical drug mechanisms. In addition, we show
that the extracted drug-SE pairs can be directly used in drug repositioning.
Conclusion: In summary, we automatically constructed a large-scale higher-level drug phenotype relationship
knowledge, which can have great potential in computational drug discovery.
Introduction
It has been increasingly recognized that similar side effects
of seemingly unrelated drugs can be caused by their com-
mon off-targets and that drugs with similar side effects are
likely to share molecular targets [1]. Therefore, systems
approaches to studying side effect relationships among
drugs and integration of this drug phenotypic data with
drug-related genetic, genomic, proteomic, and chemical
data will facilitate drug target discovery and drug reposi-
tioning. The availability of a comprehensive drug-side
effect (SE) relationship knowledge base is critical for these
tasks. Current drug phenotype-driven systems approaches
rely exclusively on drug-SE associations extracted from
FDA drug labels. However, there exists a large amount of
additional drug-SE relationship knowledge in the large
body of published biomedical literature. In this study,
we present a novel knowledge-driven approach to auto-
matically extract a large number of drug-SE pairs from
21 million published biomedical abstracts. We systema-
tically analyzed extracted drug-SE pairs in combination
with drug-related gene targets, metabolism, pathways,
gene expression and chemical structure data. We show
that these extracted drug-SE pairs have great potential
in drug discovery.1Case Western Reserve University, Cleveland OH 44106, USA
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Background
Systems approaches to studying the phenotypic relation-
ships among drugs can facilitate rapid drug target discov-
ery and drug repositioning. Computational approaches to
predicting drug targets have often been based on chemi-
cal similarity measures and docking strategies [7,16].
Similarly, many computational strategies for drug reposi-
tioning have been explored [6]. The majority of these
approaches leverage on known drug properties such as
chemical similarity [7], molecular activity similarity [12],
molecular docking [8], and gene expression profile simi-
larity [13]. In a seminal paper, Campillos et al. used phe-
notypic side-effect similarities among drugs to predict
new targets for drugs [1]. However, their analysis was
limited to drug-SE relationships derived solely from the
FDA drug labels. In one of our recent studies, we show
that much of the drug-SE association knowledge from
biomedical literature has not been captured in FDA drug
labels yet [17].
Currently, more than 21 million biomedical records are
available on MEDLINE. While many biomedical relation-
ship extraction tasks have focused on extracting relation-
ships between drugs, diseases, proteins, or genes [2,18,19],
extracting drug-SE relationships from MEDLINE has been
less explored. Recently, Gurulingappa et al. trained and
tested a supervised machine learning classifier to classify
drug-condition pairs in a set of 2972 manually annotated
case reports [4]. That study focused on a limited set of
drugs and side effects and case reports. It is unclear how
their approach can be effectively scaled up to the whole
MEDLINE in building a large-scale drug-SE relationship
knowledge base. Recently, we developed an approach in
boosting drug safety signal detection from FDA Adverse
Event Reporting System (FAERS) using evidence from
MEDLINE [20]. We developed an automatic approach to
extract anticancer drug-specific side effects from MED-
LINE by developing specific filtering and ranking schemes
[21]. We developed a pattern-based learning approach to
accurately extract drug-SE pairs from MEDLINE sen-
tences [22]. We combined automatic table classification
and relationship extraction in extracting anticancer drug-
side effect pairs from full-text articles [23]. In this study,
we present a knowledge-driven (KD) text-classification-
based approach to extract drug-SE pairs from MEDLINE
sentences. Different from our previous studies where we
extracted drug-SE pairs from unclassified sentence, here
we classified sentences into drug-SE-related and -unre-
lated before relationship extraction. Our approach is also
different from other text classification-based approaches
that often trained text classifiers using annotated training
datasets to find drug-SE-related sentences [4], instead, we
implicitly classified MEDLINE sentences using known
drug-SE pairs. Since our study did not explicitly train a
text classifier, it is highly dynamic and effective: it can
easily incorporate any changing prior knowledge and
quickly extracted drug-SE pairs from the whole MEDLINE
(21,354,075 abstracts and 119,085,682 sentences).
Approach
Our study is based on the two key observations: (1)
multiple side effects for a drug are often reported in the
same sentences or abstracts; and (2) if a sentence con-
tains a known drug-SE pair, then this sentence is likely
to be SE-relevant. Other pairs in this SE-related sen-
tence are likely to be drug-SE pairs. For example, the
sentence “At the final irinotecan dose of 50 mg/m(2),
grade 3 or higher toxicity included diarrhea (26%), neu-
tropenia (21%), nausea (18%), fatigue (16%), anorexia
(13%), and thrombosis/embolism (13%)“ (PMID
19139178) contains a known drug-SE pair “irinotecan-
diarrhea.” Based on this fact, we know that this sentence
is SE-related and that the other five pairs in this sen-
tence are likely to be drug-SE pairs. On the other hand,
the following sentence “Weekly docetaxel, cisplatin, and
irinotecan (TPC): results of a multicenter phase II trial
in patients with metastatic esophagogastric cancer “con-
tain no known drug-SE pair, therefore no pair will be
extracted from this sentences even though it contains
three drug-disease pairs. In this study, we used all
known drug-SE pairs derived from FDA drug labels as
prior knowledge to find SE-related MEDLINE sentences
and abstracts, from which many additional drug-SE
pairs that have not included in FDA drug labels are
then extracted. We compared the KD approach to a
support vector machine (SVM)-based approach.
Data and methods
The entire experimental process consists of the follow-
ing steps: (1) build a local MEDLINE search engine;
(2) develop, evaluate and compare the KD approach to a
SVM-based approach; (3) extract drug-SE pairs from
MEDLINE; and (4) systematically analyze the correlation
between drug-associated side effects and drug gene tar-
gets, metabolism genes, chemical similarity, and disease
indications.
Build a local MEDLINE search engine
We downloaded a total of 21,354,075 MEDLINE cita-
tions (119,085,682 sentences) published between 1965
and 2012 from the U.S. National Library of Medicine
http://mbr.nlm.nih.gov/Download/index.shtml. Each sen-
tence was syntactically parsed with Stanford Parser [9]
using the Amazon Cloud computing service (a total of
3,500 instance-hours with High-CPU Extra Large
Instance used). We used the publicly available informa-
tion retrieval library Lucene http://lucene.apache.org to
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create a local MEDLINE search engine with indices cre-
ated on both sentences and their corresponding parse
trees. We have recently used this local search engine in
our recent tasks of extracting disease-manifestation rela-
tionships [19] and anticancer drug-SE pairs from MED-
LINE [21].
Develop, evaluate and compare the KD approach to the
SVM-based approach
We downloaded a total of 100,049 known drug-SE pairs
from SIDER (Side Effect Resource), a public, machine-
readable side effect resource that was automatically con-
structed from FDA package inserts [10]. These pairs are
used as prior knowledge for the KD approach. Using
each drug-SE pair from the prior knowledge data as a
search query to the local MEDLINE search engine, we
retrieved all MEDLINE sentences and abstracts that
contain at least one known drug-SE pair. These sen-
tences are determined as SE-related. We then extracted
drug-SE co-occurrence pairs from these SE-relevant sen-
tences, with the restriction that both drug and SE names
must be noun phrases in the parse trees of the sen-
tences. We have recently shown that this restriction can
increase the precision of biomedical relationship extrac-
tion from MEDLINE [19-22]. The drug and SE lists
(996 drugs (generic names) and 4,199 SE terms) are
from SIDER.
We compared the drug-SE extraction from sentences
classified using the KD approach with that from sen-
tences classified using a SVM-based text classifier
(described later). For comparison, we selected ten drugs
from SIDER that are associated with the most numbers
of SEs and compared the performance of KD approach
to the SVM approach in extracting drug-SE pairs for
each of them (Figure 1). For each drug, we randomly
split its drug-SE pairs into two equal parts: training
dataset and testing dataset. For the KD approach, we
first retrieved all sentences that contain at least one of
the 10 drugs and at least one SE term from the SE lexi-
con (4,199 SE terms). We then classified these sentences
into SE-related and -unrelated. A sentence is determined
as SE-related if it contains at least one known drug-SE
pair from the training dataset (prior knowledge). We
then extracted additional drug-SE pairs from these
sentences.
For the SVM-based approach, we first classified MED-
LINE sentences into drug-SE-related and -unrelated
using a pre-trained SVM-sentence classifier. We then
extracted drug-SE co-occurrence pairs from positively
classified sentences. A two-class SVM-based sentence
classifier was trained using implementation in WeKa [5].
The positive training data consisted of a total of 320,175
sentences, each of which contained at least one known
drug-SE pairs from SIDER (the testing data for above 10
drugs were excluded). Equal number of negative sen-
tences was randomly selected from the rest of MED-
LINE sentences. The SVM-based sentence classifier
used polynomial kernel, bag-of-words feature, TF-IDF
weighting, stemming and stopwords-removal. The bag-
of-words feature was used since it is often the case that
the appearance of one specific word such as ‘toxicity’
can be used to determine whether a sentence is drug-
SE-related. The 10-fold cross validation was used in
training the SVM classifier. For both KD and SVM-
based approaches, the input sentences are the same,
which are sentences that contain at least one of the 10
drugs and at least one term from the SE lexicon. We
evaluated and compared the performance using the
same testing datasets. Precisions, recalls and F1 scores
for these 10 drugs were calculated.
Figure 1 KD approach vs. SVM approach.
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Extract drug-SE pairs from 21 Million MEDLINE records
After evaluating the KD-approach using 10 drugs, we then
scaled this approach to extract drug-SE pairs from all
MEDLINE sentences and abstracts. We used all 100,049
drug-SE pairs from SIDER as prior knowledge to classify
all MEDLINE sentences and abstracts into SE-related and
-unrelated. For the classification, we used each of the
100,049 drug-SE pairs from SIDER as a search query to
the local MEDLINE search engine. Both sentences and
abstracts containing the pair were retrieved as SE-related.
Sentences that are not retrieved are assumed to be
SE-unrelated and ignored. In total, we extracted 49,575
drug-SE pairs from sentences and 180,454 pairs from
abstracts using the drug and SE lists (996 drugs and 4,199
SE terms) we compiled from SIDER. These extracted
drug-SE pairs were used in the subsequent semantic
analysis.
Analyze the correlations between drug-associated side
effects and genetic, genomic and chemical drug
properties
Many current computational approaches for drug target
discovery [7,16] and drug repositioning[7,12,8,13] used
only lower-level genetic, genomic, and chemical drug
properties. In this study, we investigated whether the
large number of higher-level phenotypic drug-SE rela-
tionship data that we extracted from MEDLINE impli-
citly captured lower-level drug mechanism, therefore
can be leveraged for drug target discovery and drug
repositioning. In extracting drug-SE pairs from MED-
LINE, we used the generic names of FDA-approved
drugs. For the correlation analysis, we use drug generic
names to link drug-SE pairs to drug-related information
from different databases.
Correlation with drug target genes
Drug side effects are often caused by drugs acting on their
target genes. We investigated whether drug-drug pairs
that shared SEs tend to share gene targets. We down-
loaded a total of 13,635 drug-target gene associations from
DrugBank [15], a knowledge base for drugs, drug actions
and drug targets. The drug-gene pairs are comprised of
3,454 drugs and 1,816 genes. We first mapped drugs of
drug-SE pairs extracted from MEDLINE to drugs of drug-
gene pairs from DrugBank. For drug-drug pairs that share
SEs at different cutoffs, we calculated the average number
of shared gene targets.
Correlation with drug metabolizing genes
Drug metabolism plays critical role in drug-associated side
effects. We investigated whether drug-drug pairs that
shared SEs also share drug metabolism genes. We down-
loaded a total of 4,399 drug-gene pairs from PharmGKB
[14], a repository of drug pharmacogenetics information.
For drug-drug pairs that share SEs at different cutoffs, we
calculated the average number of shared metabolism genes.
Correlation with genetic, genomic and chemical drug-drug
relationships
Drug related pathway, genomic and chemical relationship
information was obtained from STITCH [11], a resource
of known and predicted interactions of chemicals and pro-
teins. In STITCH, chemicals are linked to other chemicals
and proteins by four types of relationships: chemical reac-
tions from manually curated pathway databases (“Data-
base”), literature associations (“Textmining”), similar 2D
structures (“Similarity”) and similar activities ("Experimen-
tal”) based on drug-induced perturbation on the gene
expression level [12]. We used chemical-chemical relation-
ships from curated pathway database (“Database”, 342,072
chemical-chemical pairs), chemical 2D structure (“Similar-
ity”, 607,588 chemical-chemical pairs) and gene expression
(“Experimental”, 238,380 chemical-chemical pairs). The
text mining-based co-occurrence pairs were not used
since they provide no explicit semantic relationships for
chemical-chemical pairs. For drug-drug pairs that share
SEs at different cutoffs, we calculated the average chemical
similarity scores.
Correlation with disease indications
If high-level phenotypic drug-SE relationships implicitly
capture known and unknown drug-related genetic, geno-
mic and chemical information, then drug-SE pairs may
be directly used for drug repositioning, as suggested in a
recent review article [6]. In this study, we investigated
whether drug-drug pairs that shared SEs tend to share
disease indications. We recently extracted a total of
52,000 drug-disease pairs from ClinicalTrials.gov [24], a
registry of federally and privately supported clinical trials
conducted in the United States and around the world.
The drug-disease pairs contain 2,035 drugs and 9,591 dis-
eases. For drug-drug pairs that share SEs at different cut-
offs, we calculated the average number of shared disease
indications.
Results
The KD approach is more effective than the SVM-based
approach in extracting drug-SE pairs from MEDLINE
As shown in Table 1 the KD-based approach performed
consistently better than the SVM-based approach for all
10 drugs. On average, KD achieved a precision of 0.335, a
recall of 0.509 and an F1 of 0.395. The SVM-based
approach had an average precision of 0.135, a recall of
0.900 and an F1 of 0.233. The F1 of the KD approach is
73.0% higher than that of the SVM-based approach. How-
ever the reported precision and recall may significantly
underestimate the actual precision and recall for drug-SE
pairs that we extracted from MEDLINE. For these 10
drugs, we used half of their drug-SE pairs from SIDER as
testing data, however, drug-SE association knowledge in
SIDER (derived from FDA drug labels) and from MED-
LINE has been shown to be largely complementary [17].
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In order to accurately evaluate drug-SE extractions from
MEDLINE. It will be necessary to construct a MEDLINE-
based gold standard.
Drug-associated side effects positively correlate with
drug-associated gene targets
We investigated whether drug-drug pairs that share SEs
tended to share gene targets. As shown in Figure 2, there
is positive correlation between SEs and gene targets, with
the positive correlation being much stronger for drug-SE
pairs extracted from MEDLINE sentences than those
from SIDER or MEDLINE abstracts. For instance, the
average number of shared gene targets for all drug-drug
pairs is 0.492. The number significantly increased to
0.813 for drug-drug pairs that shared at least one SEs and
to 3.161 for pairs that shared at least 100 SEs. This strong
positive correlation indicates that we may use these
extracted drug-SE pairs to discover novel drug targets or
use drug-related gene targets to predict unknown drug
side effects.
Drug-associated side effects positively correlate with
drug-associated metabolism genes
Drug-associated side effects are closely related to drug
metabolism. As shown in Figure 3, drug-drug pairs that
share SEs tended to share more metabolism genes. For
instance, the average number of shared drug metabolism
genes for all drug-drug pairs is 0.605. The number signifi-
cantly increased to 0.809 for drug-drug pairs that shared
at least one SEs and to 3.441 for drug-drug pairs sharing
at least 100 SEs. This strong positive correlation indicates
that we may achieve personalized medicine (in terms drug
toxicity) by predicting patient-specific drug side effects
based on their genotype profiles.
Table 1 Compare knowledge-driven approach (KD) to SVM for ten drugs
Drug KD SVM F1 Increase
Precision Recall F1 Precision Recall F1
Fluoxetine 0.370 0.425 0.395 0.178 0.838 0.294 34.4%
Tacrolimus 0.315 0.519 0.392 0.140 0.961 0.245 60.0%
Risperidone 0.561 0.622 0.590 0.234 0.959 0.377 56.5%
Carbamazepine 0.341 0.627 0.442 0.118 0.896 0.209 111.5%
Ibuprofen 0.230 0.406 0.294 0.106 0.891 0.189 55.6%
Olanzapine 0.463 0.492 0.477 0.180 0.921 0.301 58.5%
Morphine 0.214 0.611 0.317 0.090 0.833 0.163 94.5%
Phenytoin 0.229 0.403 0.292 0.104 0.881 0.186 57.0%
Methotrexate 0.230 0.607 0.333 0.082 0.984 0.152 119.1%
Ciprofloxacin 0.397 0.377 0.387 0.121 0.836 0.212 82.5%
Average 0.335 0.509 0.392 0.135 0.900 0.233 73.0%
Figure 2 The correlations between SEs and gene targets for
drug-SE pairs from: SIDER, MEDLINE sentences
(“KD_Sentence”), and abstracts(“KD_Abstract”).
Figure 3 The correlations between SEs and drug metabolism
genes for drug-SE pairs from: SIDER, MEDLINE sentences
(“KD_Sentence”), and abstracts(“KD_Abstract”).
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Drug-associated side effects positively correlate with
drug-associated pathways and gene expression
Genetic, genomic and structural chemical-chemical rela-
tionships have been widely used for both drug target dis-
covery and drug repositioning. We investigated whether
the phenotypic side effect similarity between drugs
captured chemical similarities as measured by chemical
structure, gene co-expression and pathway interactions.
We used chemical-chemical relationships from curated
pathway database (“Database”), chemical 2D structure
(“Similarity”) and gene expression (“Experimental”) in our
study. As shown in Figure 4, drug-drug pairs that share
SEs tend to share common pathway and 2D chemical
structure, but not gene co-expression profiles. For
instance, the average number of chemical similarity score
based on “Database” for all drug-drug combination is
7.898; the number significantly increased to 12.06 for
drug-drug pairs that share at least 10 SEs and to 27.795 for
pairs that share at least 50 SEs. The correlation curve for
chemical structure-based chemical relationships is similar
but less prominent. There is no obvious correlation
between gene expression-based drug similarity and drug
side effects. In summary, high-level phenotypic relation-
ships among drugs as determined by shared side effects
indeed reflect drug relationships at genetic and chemical
levels. Hence, systematic approaches in studying these
higher-level phenotypic drug relationships can reveal
insights into drug molecular mechanisms and offer oppor-
tunities for drug target discovery and drug repositioning.
Drug-associated side effects positively correlate with
drug-associated disease indications
In previous sections, we have shown that drug-associated
side effects reflect drug-associated molecular mechanism.
In this section, we investigated whether the large number
of drug-SE pairs that we extracted from MEDLINE have
potential in being directly used in drug repositioning. As
shown in Figure 5, drug-drug pairs that share SEs share
significantly more disease indications than pairs sharing
no SEs. The positive correlation is much stronger when
drug-SE pairs extracted from MEDLINE sentences were
used than pairs from SIDER or MEDLINE abstracts. For
instance, the average number of shared drug indications
for all possible drug-drug pairs is 1.074. The number sig-
nificantly increased to 2.281 for pairs that shared at least
one SEs and to 21.164 for drug-drug pairs sharing at least
100 SEs. This strong positive correlation between drug-
associated SEs and drug-associated disease treatments
indicates that we may directly use the observed drug side
effects for drug repositioning. For example, if two drugs
often have the same side effects when used in patients, we
can reason that these two drugs have similar underlying
mechanisms (share genetic targets, pathways, gene expres-
sion or chemical structures etc) and can be used to treat
the same diseases. The advantage in using high-level phe-
notypic drug side effect information compared to lower-
level genetic and chemical information is that is that we
can reposition existing drugs for new disease indications
without knowing underlying drug mechanisms or disease
etiology, which largely remain unknown.
Discussion
Our current study has several limitations and can be
significantly improved in future studies. First, we used
drug-SE pairs from SIDER as prior knowledge for the
KD approach. The overall performance depends on the
accuracy and comprehensiveness of the SIDER database.
Figure 4 The correlation between shared SEs and chemical
similarity: “Database”, “Experimental” and “Similarity”.
Figure 5 The correlation between SEs and disease indications
for drug-SE pairs from: SIDER, MEDLINE sentences
(“KD_Sentence”), and abstracts (“KD_Abstract”).
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Errors and uncertainties in the knowledge base can propa-
gate into the relationship extraction process and adversely
affect the precision. For example, the drug-disease treat-
ment pair ‘ondansetron-pain’ was incorrectly specified as a
drug-SE pair in SIDER. Because of this error, our algo-
rithm classified the following sentence as SE-related:
“Ondansetron, lidocaine, tramadol, and fentanyl were
effective in preventing and decreasing the level of rocuro-
nium injection pain“ (PMID 12032018). Three additional
pairs (lidocaine-pain, tramadol-pain, and fentanyl-pain)
were incorrectly extracted as drug-SE pairs. Since SIDER
was constructed from FDA drug labels using text-mining
approaches, errors may be inevitable for completely auto-
matic method. Currently, we are manually extracting
drug-associated side effects from FDA drug labels. Second,
our algorithm cannot extract correct pairs from sentences
with multiple drugs and multiple side effect names (n ×
m), even though the sentences are side effect-related. For
example, sentence “... decreases in hemoglobin, nausea/
vomiting, and hyperbilirubinemia were observed to be
influenced by the previous use of irinotecan (OR = 3.07,
P = 0.003), mitomycin (OR = 2.28, P = 0.004), and cispla-
tin (OR = 1.60, P = 0.007), respectively” (PMID:
17577624). Three drugs and three SEs are specified in the
sentence, but only three, instead of 9 (3 × 3) are valid
drug-SE pairs. This is a difficult problem for not only the
KD approach but also for automatic relationship extrac-
tion in general. In this case, human curation may be
necessary. Even with the above mentioned limitations, we
demonstrated that the large number of drug-SE pairs
extracted from MEDLINE reflect drug-related genetic,
genomic and chemical information and can have potential
in computational drug target discovery and drug reposi-
tioning. Currently, we are developing integrative systems
approaches for drug repositioning by fully exploiting data
ranging from lower level genetic connections to immediate
layer genomic data to higher level phenotype data in order
to build integrative models of genetic, genomic, and phe-
notypic complexity.
Conclusions
We have developed a novel KD approach in extracting a
total of 49,575 drug-SE pairs from 119,085,682 MELDINE
sentences and 180,454 pairs from 21,354,075 MEDLINE
abstracts (records). We show that the KD approach per-
formed significantly better that a SVM-based machine
approach. We demonstrated that this large-scale drug-SE
association database that we have built provides an invalu-
able data resource for computational drug target discovery
and drug repositioning.
Funding
RX is funded by Case Western Reserve University/Cle-
veland Clinic CTSA Grant (UL1 RR024989), the Eunice
Kennedy Shriver National Institute Of Child Health &
Human Development of the National Institutes of
Health under Award Number DP2HD084068, the Train-
ing grant in Computational Genomic Epidemiology of
Cancer (CoGE) (R25 CA094186-06), and Grant #IRG-
91-022-18 to the Case Comprehensive Cancer Center
from the American Cancer Society. QW is partly funded
by ThinTek LLC.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Xu and Wang have jointly conceived the idea, designed and implemented
the algorithms and prepared the manuscript.
Declarations
Publication charges for this article have been funded by the Training
grant in Computational Genomic Epidemiology of Cancer (CoGE)
(R25 CA094186-06).
This article has been published as part of BMC Bioinformatics Volume 16
Supplement 5, 2015: Selected articles from the 10th International
Symposium on Bioinformatics Research and Applications (ISBRA-14):
Bioinformatics. The full contents of the supplement are available online at
http://www.biomedcentral.com/bmcbioinformatics/supplements/16/S5.
Authors’ details
1Case Western Reserve University, Cleveland OH 44106, USA. 2ThinTek, LLC,
Palo Alto CA 94306, USA.
Published: 18 March 2015
References
1. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P: Drug target
identification using side-effect similarity. Science 2008, 321(5886):263-266.
2. Cohen KB, Hunter LE: Text Mining for Translational Bioinformatics. PLoS
computational biology 2013, 9(4):e1003044.
3. Fliri AF, Loging WT, Thadeio PF, Volkmann RA: Analysis of drug-induced
effect patterns to link structure and side effects of medicines. Nature
chemical biology 2005, 1(7):389-397.
4. Gurulingappa H, Mateen-Rajput A, Toldo L: Extraction of potential adverse
drug events from medical case reports. Journal of biomedical semantics
2012, 3(1):15.
5. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, Witten IH: The
WEKA data mining software: an update. ACM SIGKDD, Explorations
Newsletter 2009, 11(1):10-18.
6. Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P: Computational
drug repositioning: From data to therapeutics. Clinical Pharmacology and
Therapeutics 2013.
7. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Roth BL:
Predicting new molecular targets for known drugs. Nature 2009,
462(7270):175-181.
8. Kinnings SL, Liu N, Buchmeier N, Tonge PJ, Xie L, Bourne PE: Drug
discovery using chemical systems biology: repositioning the safe
medicine Comtan to treat multi-drug and extensively drug resistant
tuberculosis. PLoS computational biology 2009, 5(7):e1000423.
9. Klein D, Manning CD: Accurate unlexicalized parsing. Proceedings of the
41st Annual Meeting on Association for Computational Linguistics. Association
for Computational Linguistics 2003, 1:423-430.
10. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P: A side effect resource to
capture phenotypic effects of drugs. Molecular systems biology 2010, 6(1).
11. Kuhn M, Szklarczyk D, Franceschini A, von Mering C, Jensen LJ, Bork P:
STITCH 3: zooming in on proteinchemical interactions. Nucleic acids
research 2012, 40(D1):D876-D880.
12. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Golub TR: The
Connectivity Map: using gene-expression signatures to connect small
molecules, genes, and disease. Science Signalling 2006, 313(5795):1929.
Xu and Wang BMC Bioinformatics 2015, 16(Suppl 5):S6
http://www.biomedcentral.com/1471-2105/16/S5/S6
Page 7 of 8
13. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A,
Butte AJ: Discovery and preclinical validation of drug indications using
compendia of public gene expression data. Sci Transl Med 2011,
3(96ra):77.
14. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong Li, Sangkuhl K, Thorn CF,
Altman RB, Klein TE: Pharmacogenomics Knowledge for Personalized
Medicine. Clinical Pharmacology and Therapeutics 2012, 92(4):414-417.
15. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P,
Woolsey J: DrugBank: a comprehensive resource for in silico drug
discovery and exploration. Nucleic acids research 2006, 34(suppl 1):
D668-D672.
16. Xie L, Evangelidis T, Xie L, Bourne PE: Drug discovery using chemical
systems biology: weak inhibition of multiple kinases may contribute to
the anti-cancer effect of nelfinavir. PLoS computational biology 2011, 7(4):
e1002037.
17. Xu R, Wang Q: Automatic signal prioritizing and filtering approaches in
detecting post-marketing cardiovascular events associated with targeted
cancer drugs from the FDA Adverse Event Reporting System (FAERS).
Journal of Biomedical Informatics 2014, 47:171-7.
18. Xu R, Wang Q: A semi-supervised approach to extract
pharmacogenomics-specific drug-gene pairs from biomedical literature
for personalized medicine. Journal of Biomedical Informatics 2013, 46(4),
585-593.
19. Xu R, Li L, Wang Q: Towards building a disease-phenotype relationship
knowledge base: large scale extraction of disease-manifestation
relationship from literature. Bioinformatics 2013.
20. Xu R, Wang Q: Large-scale combining signals from both biomedical
literature and the FDA Adverse Event Reporting System (FAERS) to
improve post-marketing drug safety signal detection. BMC Bioinformatics
2014, 15:17.
21. Xu R, Wang Q: Automatic construction and integrated analysis of a
cancer drug side effect knowledge base. Journal of the American Medical
Informatics Association 2014.
22. Xu R, Wang Q: Automatic construction of a large-scale and accurate
drug-side-effect association knowledge base from biomedical literature.
Journal of Biomedical Informatics, J Biomed Inform 2014, 51:191-9.
23. Xu R, Wang Q: Combining automatic table classification and relationship
extraction in extracting anticancer drug-side effect pairs from full-text
articles. Journal of Biomedical Informatics 2014.
24. Xu R, Wang Q: Large-scale extraction of drug-disease treatment pairs
from biomedical literature for drug repurposing. BMC Bioinformatics 2013,
14(1):181.
doi:10.1186/1471-2105-16-S5-S6
Cite this article as: Xu and Wang: Comparing a knowledge-driven
approach to a supervised machine learning approach in large-scale
extraction of drug-side effect relationships from free-text biomedical
literature. BMC Bioinformatics 2015 16(Suppl 5):S6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Xu and Wang BMC Bioinformatics 2015, 16(Suppl 5):S6
http://www.biomedcentral.com/1471-2105/16/S5/S6
Page 8 of 8
